WZ811

WZ811 is an orally active, highly potent competitive antagonist of CXCR4. WZ811 efficiently inhibits CXCR4/SDF-1 (or CXCL12) -mediated modulation of cAMP levels (EC50=1.2 nM) and SDF-1 induced Matrigel invasion in cells (EC50=5.2 nM) [1].

Product Specifications

CAS Number

[55778-02-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/wz811.html

Purity

99.80

Solubility

DMSO : 10 mg/mL (ultrasonic)

Smiles

C1(CNC2=NC=CC=C2)=CC=C(CNC3=NC=CC=C3)C=C1

Molecular Formula

C18H18N4

Molecular Weight

290.36

Precautions

H302, H315, H319, H335

References & Citations

[1]WZ811, et al. Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50 (23) :5655-64.|[2]Li SH, et al. Suppression of chronic lymphocytic leukemia progression by CXCR4 inhibitor WZ811. Am J Transl Res. 2016 Sep 15;8 (9) :3812-3821.